AKT1 and neoplasm: On the other hand, a loss of PTEN, a negative regulator of the PI3K/AKT/mTOR pathway, is present in approximately 60% of mCRPC patients [60] which is related to worse prognosis, treatment resistance, tumor grade, tumor stage, and risk of recurrence [3,61].